Integral Diagnostics's quarterly market cap
declined
from Dec. 2024 (A$1,081.4 Mil) to Jun. 2025 (A$945.4 Mil) but then
increased
from Jun. 2025 (A$945.4 Mil) to Dec. 2025 (A$945.8 Mil).
Integral Diagnostics's annual market cap
declined
from Jun. 2023 (A$764.3 Mil) to Jun. 2024 (A$624.6 Mil) but then
increased
from Jun. 2024 (A$624.6 Mil) to Jun. 2025 (A$945.4 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Integral Diagnostics's Enterprise Value for Today is A$1,316.8 Mil.
Integral Diagnostics (ASX:IDX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Integral Diagnostics Market Cap Related Terms
Integral Diagnostics Market Cap Historical Data
* Premium members only.
The historical data trend for Integral Diagnostics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Integral Diagnostics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integral Diagnostics Market Cap vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Integral Diagnostics's Market Cap distribution charts can be found below:
* The bar in red indicates where Integral Diagnostics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Integral Diagnostics's Market Cap for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integral Diagnostics (ASX:IDX) has a Market Cap of A$746.1 Mil as of Jun. 27, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Integral Diagnostics and its competitors. According to the industry distribution chart, Integral Diagnostics ranks #63 out of 219 companies in the Medical Diagnostics & Research industry, placing it in the top 28.8%.
Is Integral Diagnostics' Market Cap too high?
Integral Diagnostics' current Market Cap is A$746.1 Mil. Based on the distribution chart, Integral Diagnostics ranks #63 out of 219 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Integral Diagnostics has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integral Diagnostics' Market Cap compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integral Diagnostics ranks #63 out of 219 companies for Market Cap. This puts Integral Diagnostics in the upper half of its industry. The industry median Market Cap is 55.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Diagnostics & Research company?
The median Market Cap among Medical Diagnostics & Research companies is 55.76, based on 219 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Integral Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median Market Cap is 55.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integral Diagnostics's current Market Cap is A$746.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integral Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Integral Diagnostics (ASX:IDX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$2.78, compared to a current price of A$2.00 — trading 28.1% below its estimated fair value. The current Market Cap is A$746.1 Mil. Integral Diagnostics' overall GF Score™ is 75/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Integral Diagnostics (ASX:IDX), the current Market Cap is A$746.1 Mil as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integral Diagnostics (ASX:IDX) Overvalued in 2026?
Based on GuruFocus' analysis, Integral Diagnostics stock appears to be undervalued.
The current stock price of A$2.00 is trading 28.1% below its estimated GF Value™ of A$2.78.
GuruFocus considers Integral Diagnostics to be Modestly Undervalued.
Key valuation signals for ASX:IDX:
Market Cap: A$746.1 Mil
GF Value™: A$2.78 vs. price of A$2.00 (28.1% below fair value)
No single metric tells the full story. See the ASX:IDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integral Diagnostics is a major Australian diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.
75GF Score
Get the complete analysis for ASX:IDX
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IDX has been successfully added to your 
